Biological E partners with Bavarian Nordic to expand access to Chikungunya Vaccine in low- and middle-income countries.

Biological E Limited (BE) on Tuesday announced a strategic partnership with Bavarian Nordic A/S (OMX: BAVA) to expand access ...

Several observations point toward the possibility of a vaccine development strategy ... and MVA Liver stage IIa LSA1 WRAIR, GSK, MVI Recombinant protein, AS02/AS01 Liver stage I/IIa LSA3 Institut ...

COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA ® for active ...

Hyderabad: Biological E. Limited has announced a strategic partnership with Bavarian Nordic A/S to expand access to Bavarian ...

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic ...

Biological E (BE) has partnered with Bavarian Nordic to produce the Chikungunya vaccine, VIMKUNYA CHIKV VLP, for low and ...

HCV vaccines ... proteins Treatment-naive HCV patients Decrease of HCV viral load associated with a boost of HCV-specific T-cell response [108,205] Intercell AG IC41: poly-l-arginine-adjuvanted ...

This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya ...

Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya ...